[go: up one dir, main page]

UA93922C2 - Process for production of peptides, specifically recognizing the cells of particular type, meant for therapeutic goals - Google Patents

Process for production of peptides, specifically recognizing the cells of particular type, meant for therapeutic goals

Info

Publication number
UA93922C2
UA93922C2 UAA200902499A UAA200902499A UA93922C2 UA 93922 C2 UA93922 C2 UA 93922C2 UA A200902499 A UAA200902499 A UA A200902499A UA A200902499 A UAA200902499 A UA A200902499A UA 93922 C2 UA93922 C2 UA 93922C2
Authority
UA
Ukraine
Prior art keywords
cells
peptides
particular type
production
therapy
Prior art date
Application number
UAA200902499A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Михаил Викторович Разуменко
Original Assignee
Михаил Викторович Разуменко
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Михаил Викторович Разуменко filed Critical Михаил Викторович Разуменко
Priority to UAA200902499A priority Critical patent/UA93922C2/en
Priority to RU2011140269/10A priority patent/RU2528739C2/en
Priority to PCT/UA2009/000011 priority patent/WO2010107405A1/en
Publication of UA93922C2 publication Critical patent/UA93922C2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1037Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/02Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to genetic engineering, in particular to the processes for production of peptides, specifically recognizing the cells of particular type, which can be used in diagnostics, therapy, and pharmaceutics. According to the invention, the large amount of libraries of random peptides are constructed on the basis of oligonucleotide fragments, coding them, by means of fragmentation of total RNA of cells of particular type and cells of the other types, which can be involved in pathological process and influence on its diagnostics and therapy. The mentioned fragments are cloned in right orientation into the vector on the basis of bacteriophage. After that library screening is realized with using of combination of cells of particular type and cells of the other types in several stages for production of groups of peptides, specifically recognizing the cells of selected type as part of vector. From the produced peptides the individual peptides are isolated and tested as part of phage particles with using of combined tests for confirmation of theirs specificity towards the cells of particular type. For production of pure peptides the matrixes are designed on the basis of amino acid sequences of peptides as part of phage particles, from whish the sequences of new peptides are read and they are chemically synthesized, with further confirmation of specific recognition of cells of selected type. The conducting of such method allows to obtain peptides, recognizing cells of particular type with high level of specificity and selectiveness, which can be used for delivery of drugs to the place of theirs direct action for the purpose of prevention and/or therapy, connected with disorder of function of cells of particular type, for example, vascular smooth muscle cells, and also for immediate using of produced peptides as a dosage form in therapy, and also for diagnostics of disorder of function of cells of particular type and to prognosticate theirs treatment.
UAA200902499A 2009-03-20 2009-03-20 Process for production of peptides, specifically recognizing the cells of particular type, meant for therapeutic goals UA93922C2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
UAA200902499A UA93922C2 (en) 2009-03-20 2009-03-20 Process for production of peptides, specifically recognizing the cells of particular type, meant for therapeutic goals
RU2011140269/10A RU2528739C2 (en) 2009-03-20 2009-03-27 Method of producing peptides specifically identifying certain types of cells and intended for therapeutic purposes
PCT/UA2009/000011 WO2010107405A1 (en) 2009-03-20 2009-03-27 Method for producing peptides which specifically recognize cells of particular types and can be used for therapeutic purposes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UAA200902499A UA93922C2 (en) 2009-03-20 2009-03-20 Process for production of peptides, specifically recognizing the cells of particular type, meant for therapeutic goals

Publications (1)

Publication Number Publication Date
UA93922C2 true UA93922C2 (en) 2011-03-25

Family

ID=42739879

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200902499A UA93922C2 (en) 2009-03-20 2009-03-20 Process for production of peptides, specifically recognizing the cells of particular type, meant for therapeutic goals

Country Status (3)

Country Link
RU (1) RU2528739C2 (en)
UA (1) UA93922C2 (en)
WO (1) WO2010107405A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2572710C1 (en) * 2014-08-13 2016-01-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарёва" Compound of nibentane and amino acid possessing antiarhythmic activity and method for producing it
DK3209819T3 (en) * 2014-10-22 2024-05-21 48Hour Discovery Inc GENETIC ENCODING OF CHEMICAL POST-TRANSLATIONAL MODIFICATION FOR PHAGE-DISPLAYED LIBRARIES
EP3827116A4 (en) 2018-07-23 2022-05-11 The Governors of the University of Alberta GENETICALLY ENCODED BICYCLIC PEPTIDE LIBRARIES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DE60331422D1 (en) * 2002-01-22 2010-04-08 Evrogen Ip FLUORESCENT PROTEIN FROM AEQUOREA COERULESCENS AND ITS USES
RU2263146C2 (en) * 2003-07-10 2005-10-27 Михаил Викторович Разуменко Method for preparing bacteriophages binding specifically with target-cells and designated for therapeutic aims
UA66110A (en) * 2003-07-28 2004-04-15 Mykhailo Viktorovych Razumenko A method for the preparation of specific peptides for therapeutic purposes

Also Published As

Publication number Publication date
RU2011140269A (en) 2013-04-27
RU2528739C2 (en) 2014-09-20
WO2010107405A1 (en) 2010-09-23

Similar Documents

Publication Publication Date Title
Wang et al. RNA-based diagnostic markers discovery and therapeutic targets development in cancer
Zhao et al. RNA delivery biomaterials for the treatment of genetic and rare diseases
Kim et al. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs
UA101155C2 (en) Modified polypeptide of factor vii (fvii) and its using
MX359953B (en) Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein.
MX342933B (en) Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein.
WO2008142164A3 (en) Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
WO2007104529A3 (en) Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
TN2012000372A1 (en) Fibronectin based scaffold domain proteins that bind il-23
JP2010528008A5 (en)
WO2002102323A3 (en) Novel human histone deacetylases
EP4282967A3 (en) Method for changing the intercellular mobility of an mrna
EP4616914A3 (en) Polypeptides binding to human complement c5
UA93922C2 (en) Process for production of peptides, specifically recognizing the cells of particular type, meant for therapeutic goals
WO2004014222A3 (en) Diagnosis and treatment of tuberous sclerosis
JP2015522264A5 (en)
EP4285911A3 (en) Methods and compositions for diagnosis and treatment of cancer
WO2010018950A3 (en) Protein scaffold library based on kringle domain structure and uses thereof
Xie et al. Identification of Viscum album L. miRNAs and prediction of their medicinal values
MX2022014326A (en) Multispecific proteins.
MX2021000677A (en) Therapeutic dendrimer.
Alammari et al. Hidden regulators: the emerging roles of lncRNAs in brain development and disease
Loy et al. Lifestyle and horizontal gene transfer-mediated evolution of Mucispirillum schaedleri, a core member of the murine gut microbiota. mSystems 2: e00171-16
SA521422323B1 (en) Hybrid Promoters and Their Uses in Therapy, Notably for Treating Type II Collagenopathies
WO2008049643A3 (en) Gd2 peptide mimotopes for anticancer vaccination